BioSpace News Archive

As of , BioArctic AB will move to the Large Cap listing on the Nasdaq Stockholm stock exchange.

Blacksmith Medicines, Inc., and Forge Therapeutics, announce that the companies have signed a definitive merger agreement to leverage their combined chemistry platforms, creating a leading biopharma dedicated to discovering and developing medicines targeting a large class of proteins called metalloenzymes, with initial focus on oncology and infection.

“A surgeon’s scalpel handle has not significantly changed since it was first introduced 100 years ago,” says Dr. Steven Hacker, Founder of Nano Surgical, LLC and Inventor of Lumohs, a patented reusable scalpel that enables shadowless illumination millimeters from surgical site.

Alteogen Inc. announced that the company has entered into an exclusive license agreement with Sandoz AG.

Datar Cancer Genetics Inc announced that the US Food and Drug Administration has granted ‘Breakthrough Device Designation’ for its ‘TriNetra™-Glio’, a blood test to help in the diagnosis of brain tumors.

Gift of Life Biologics announced that accomplished biopharmaceutical leader Eric Strati, Pharm.D. MBA has joined the firm as its Chief Executive Officer.

Hansa Biopharma announces that it has attained reimbursement in the Czech Republic for its first-in-class treatment, Idefirix®, for the desensitization treatment of highly sensitized adult patients prior to kidney transplant from a deceased donor.

United Therapeutics Corporation announced that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the 41st annual J.P. Morgan Healthcare Conference in San Francisco.

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that China’s National Medical Products Administration has formally accepted its New Drug Application for ciltacabtagene autoleucel.

Ascletis Pharma Inc. was recently informed that on December 29, 2022, Viking Therapeutics, Inc., a pharmaceutical company in the United States, filed certain complaints against Ascletis, its founder Dr. Jinzi Jason WU and certain subsidiaries of Ascletis in connection with the drug candidates ASC41 and ASC43F.